Accelerating drug development through collaboration: the Hepatitis C Drug Development Advisory Group.
Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's(1) HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.
School of Public Health, University of California-Berkeley, Berkeley, California, USA.
C
C
Hutchison
InnovaTID, Cambridge, Massachusetts, USA.
A
A
Kwong
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
S
S
Ray
Division of Antiviral Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
K
K
Struble
Treatment Action Group, New York, New York, USA.
T
T
Swan
Forum for Collaborative HIV Research, University of California-Berkeley, Washington, DC, USA.
V
V
Miller
D026683:Advisory Committees / Q000331:legislation & jurisprudence / Q000639:trends*; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D003299:Cooperative Behavior; D055808:Drug Discovery / Q000331:legislation & jurisprudence / Q000639:trends*; D016174:Hepacivirus / Q000187:drug effects / Q000502:physiology; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans
D000998:Antiviral Agents